The PBC Journey: Learning
Newly diagnosed? Read the latest insights on what to expect next.
-
-
High neutrophil-to-lymphocyte ratio may predict poor outcomes in PBC treatment
-
Ipsen, Genfit score FDA priority review for investigational PBC therapy
-
Ipsen-Genfit’s elafibranor shows promise in phase 3 PBC trial
-
Holistic approaches to complement medical treatment for PBC
-
Obeticholic acid may reduce the risk of negative outcomes in PBC
-
CymaBay submits New Drug Application for PBC treatment
